HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 64, Number 7, April 12, 2005 Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wingerchuk, D. M. Articles by Rodriguez, M. Search for Related Content PubMed PubMed Citation Articles by Wingerchuk, D. M. Articles by Rodriguez, M. Related Collections All Clinical trials Clinical trials Randomized controlled (CONSORT agreement) Multiple sclerosis

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis

From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.

Address correspondence and reprint requests to Dr. Dean M. Wingerchuk, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259; e-mail wingerchuk.dean{at}mayo.edu

Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.

Editorial, see page 1111

See also page 1139.

The Mayo Foundation supported the study. M.R. was supported by a program project grant from the NIH (NS-38468).

Disclosure: The authors have nothing to disclose.

Received August 26, 2004. Accepted in final form December 9, 2004.

This article has been cited by other articles:

				P Hagell and L Brundin Towards an understanding of fatigue in Parkinson disease J. Neurol. Neurosurg. Psychiatry, May 1, 2009; 80(5): 489 - 492. [Abstract] [Full Text] [PDF]

				D. Kos, E. Kerckhofs, G. Nagels, M.B. D'hooghe, and S. Ilsbroukx Origin of Fatigue in Multiple Sclerosis: Review of the Literature Neurorehabil Neural Repair, February 1, 2008; 22(1): 91 - 100. [Abstract] [PDF]

				K. van Kessel, R. Moss-Morris, E. Willoughby, T. Chalder, M. H. Johnson, and E. Robinson A Randomized Controlled Trial of Cognitive Behavior Therapy for Multiple Sclerosis Fatigue Psychosom Med, February 1, 2008; 70(2): 205 - 213. [Abstract] [Full Text] [PDF]

				D. M. Wingerchuk and M. Rodriguez Premenstrual multiple sclerosis pseudoexacerbations: role of body temperature and prevention with aspirin. Arch Neurol, July 1, 2006; 63(7): 1005 - 1008. [Abstract] [Full Text] [PDF]

				MS Fatigue: Aspirin Works, Modafinil Doesn't . . . Journal Watch Psychiatry, May 18, 2005; 2005(518): 6 - 6. [Full Text]

				S. R. Schwid and T. J. Murray Treating fatigue in patients with MS: One step forward, one step back Neurology, April 12, 2005; 64(7): 1111 - 1112. [Full Text] [PDF]